Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $15.83.
Several research analysts have commented on OCUL shares. StockNews.com cut shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Friday, April 5th. JMP Securities decreased their target price on shares of Ocular Therapeutix from $24.00 to $22.00 and set a “market outperform” rating for the company in a report on Wednesday, May 8th. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of Ocular Therapeutix in a research report on Friday, June 14th. TD Cowen lowered shares of Ocular Therapeutix from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 21st. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research report on Friday, June 21st.
View Our Latest Research Report on OCUL
Institutional Investors Weigh In On Ocular Therapeutix
Ocular Therapeutix Stock Down 3.1 %
OCUL stock opened at $8.17 on Thursday. The company has a quick ratio of 21.29, a current ratio of 21.39 and a debt-to-equity ratio of 0.16. Ocular Therapeutix has a fifty-two week low of $2.00 and a fifty-two week high of $11.31. The firm’s 50-day simple moving average is $6.47 and its 200 day simple moving average is $6.85. The stock has a market cap of $1.27 billion, a PE ratio of -6.00 and a beta of 1.30.
Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.06). Ocular Therapeutix had a negative return on equity of 76.64% and a negative net margin of 192.61%. The firm had revenue of $14.77 million during the quarter, compared to analyst estimates of $15.43 million. As a group, sell-side analysts predict that Ocular Therapeutix will post -0.98 EPS for the current year.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Read More
- Five stocks we like better than Ocular Therapeutix
- What is the Euro STOXX 50 Index?
- Survey: Top 175 Fittest Retirement Locations in America
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- What is a Special Dividend?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.